Galectin Therapeutics to Present at Upcoming Conferences

Thursday, January 28, 2016 1:00 PM UTC

NORCROSS, Ga., Jan. 28, 2016 -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today Peter G. Traber, MD, the Company’s president, chief executive officer and chief medical officer will present at the 18^th Annual BIO CEO & Investor Conference on February 8, 2016, at 10:30 a.m. and at Source Capital Group’s 2016 Disruptive Growth & Healthcare Conference on February 11, 2016, at 12:00 p.m. Eastern Standard Time.

The BIO CEO presentation will be webcast, and may be found on the company’s website at www.galectintherapeutics.com.

About Galectin Therapeutics

Galectin Therapeutics is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, which are key mediators of biologic function. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. The Company is pursuing a development pathway to clinical enhancement and commercialization for its lead compounds in liver fibrosis and cancer. Additional information is available at www.galectintherapeutics.com.

About BIO CEO & Investor Conference

The BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies. Because our mission is to support industry-wide success, we present a broad and unbiased view of investment opportunities. Each year the BIO CEO & Investor Conference provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. The conference features issue-oriented plenary sessions, educational sessions focused on hot therapeutic areas and key business issues, company presentations, one-on-one meetings, and networking opportunities.

https://www.bio.org/events/conferences/bio-ceo-investor-conference

About Source Capital Group

Source Capital Group, Inc. was founded in 1992 on the belief that the best investment advice should be independent, unbiased and tailor-made for the individual client’s needs. Source Capital began as a boutique investment banking firm specializing in small to medium sized transactions. It has grown to include businesses in general securities, emerging market securities, distressed and high yield debt securities, in addition to its investment banking activity. http://www.sourcegrp.com/

Contacts
Jack Callicutt, Chief Financial Officer
(678) 620-3186
[email protected]

LHA
Kim Golodetz
(212) 838-3777
[email protected]

Galectin Therapeutics and its associated logo is a registered trademark of Galectin Therapeutics Inc.

Editor's Picks

Breathing through your nose when you exercise may make your runs easier

Entrepreneurs are facing a mental health crisis — here's how to help them

Are fish oil supplements as healthy as we think? And is eating fish better?

Will AI kill our creativity? It could – if we don’t start to value and protect the traits that make us human

Does AI have a right to free speech? Only if it supports our right to free thought

How can I lower my cholesterol? Do supplements work? How about psyllium or probiotics?

Why we need to set limits on sperm donation

Aging with a healthy brain: How lifestyle changes could help prevent up to 40% of dementia cases

Seven techniques to avoid weight regain, approved by experts

Galectin Therapeutics to Present at Upcoming Conferences

Editor's Picks

Welcome to EconoTimes